Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines.
about
Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines.Digitoxin and its synthetic analog MonoD have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxelPhase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experienceGemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patientsRole of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer.Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.Gemcitabine and taxanes in metastatic breast cancer: a systematic review.Schedule-Dependent Effect of Epigallocatechin-3-Gallate (EGCG) with Paclitaxel on H460 Cells.Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors.Schedule dependent synergy of gemcitabine and doxorubicin: Improvement of in vitro efficacy and lack of in vitro-in vivo correlation.
P2860
Q24813485-03EF31CE-32D9-4A12-9C1C-F89E3BC339ABQ28397351-9BE379AF-33C8-4FF3-97A0-3A932B471A29Q33237182-C3EA69E3-42C1-4488-AB16-193288072719Q33344322-57D0D2D0-B0EB-4084-9C64-F9ED60F15A21Q35803848-FE10B98F-DE56-4807-92D0-5B240CB9180AQ36028719-A1871C11-3EA5-4E1D-BF8B-F50D593ABA0DQ36671058-33B480C7-9179-4F86-9D5C-34F6B9D99672Q37098132-DB3B628F-3A4D-4D64-864E-0A5414F373E5Q38689830-68F3039F-3659-4382-8DD8-5E3E901D3540Q38746649-5626F084-C29D-4598-BCC4-B4ED15A162F3Q41905474-2837345F-EC06-4122-AE4A-52D83F8691FBQ44010183-F87D2C70-9D8B-4983-9BC7-BF5CDD2EC8A4Q44439083-FB9A4DDC-16E2-4762-805C-D738921973D2Q53465288-B86A60F9-81A1-4CBC-92B1-4B49A90241D2
P2860
Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Schedule-dependent interaction ...... uman breast cancer cell lines.
@en
type
label
Schedule-dependent interaction ...... uman breast cancer cell lines.
@en
prefLabel
Schedule-dependent interaction ...... uman breast cancer cell lines.
@en
P2093
P1476
Schedule-dependent interaction ...... uman breast cancer cell lines.
@en
P2093
C Milandri
D Casadei Giunchi
F Barzanti
G L Frassineti
M Dal Susino
P304
P356
10.1002/(SICI)1097-0215(19990129)80:3<413::AID-IJC13>3.0.CO;2-I
P577
1999-01-01T00:00:00Z